Credit Suisse’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-150,752
| Closed | -$3.56M | – | 3056 |
|
|
2023
Q4 | $3.56M | Sell |
150,752
-10,913
| -7% | -$194K | ﹤0.01% | 1533 |
|
|
2023
Q3 | $2.41M | Sell |
161,665
-10,392
| -6% | -$138K | ﹤0.01% | 1708 |
|
|
2023
Q2 | $1.88M | Buy |
172,057
+106,311
| +162% | +$990K | ﹤0.01% | 1953 |
|
|
2023
Q1 | $573K | Buy |
+65,746
| New | +$526K | ﹤0.01% | 2677 |
|
|
2021
Q2 | – | Sell |
-35,269
| Closed | -$160K | – | 4654 |
|
|
2021
Q1 | $160K | Sell |
35,269
-4,197
| -11% | -$22.6K | ﹤0.01% | 4156 |
|
|
2020
Q4 | $226K | Buy |
+39,466
| New | +$299K | ﹤0.01% | 4064 |
|
|
2020
Q3 | – | Sell |
-490,223
| Closed | -$1.71M | – | 4163 |
|
|
2020
Q2 | $1.71M | Sell |
490,223
-122,067
| -20% | -$352K | ﹤0.01% | 2507 |
|
|
2020
Q1 | $907K | Buy |
612,290
+576,781
| +1,624% | +$968K | ﹤0.01% | 2724 |
|
|
2019
Q4 | $70K | Sell |
35,509
-11,085
| -24% | -$41.6K | ﹤0.01% | 4091 |
|
|
2019
Q3 | $238K | Buy |
46,594
+3,005
| +7% | +$18.2K | ﹤0.01% | 3802 |
|
|
2019
Q2 | $311K | Sell |
43,589
-786,518
| -95% | -$8.91M | ﹤0.01% | 3664 |
|
|
2019
Q1 | $11M | Buy |
830,107
+789,594
| +1,949% | +$8.4M | 0.01% | 1182 |
|
|
2018
Q4 | $319K | Sell |
40,513
-430
| -1% | -$4.09K | ﹤0.01% | 3487 |
|
|
2018
Q3 | $453K | Sell |
40,943
-17,209
| -30% | -$214K | ﹤0.01% | 3356 |
|
|
2018
Q2 | $780K | Buy |
58,152
+36,663
| +171% | +$459K | ﹤0.01% | 3189 |
|
|
2018
Q1 | $279K | Sell |
21,489
-7,946
| -27% | -$98.7K | ﹤0.01% | 3596 |
|
|
2017
Q4 | $271K | Buy |
29,435
+13,593
| +86% | +$116K | ﹤0.01% | 3662 |
|
|
2017
Q3 | $127K | Buy |
+15,842
| New | +$107K | ﹤0.01% | 4045 |
|
Other funds holding CBAY
Credit Suisse's CBAY Position: Q1 2024 in Review
Credit Suisse sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 150,752 shares — an estimated $3.56M sold.
Credit Suisse first reported a position in CBAY in Q3 2017 and held it in 18 quarters. The position peaked at $11M in Q1 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Credit Suisse reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Credit Suisse sold 150,752 Cymabay Therapeutics shares in Q1 2024, an estimated $3.56M.
- Credit Suisse first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 18 quarters.
- Credit Suisse's Cymabay Therapeutics position peaked at $11M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.